XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 53.76

Change

+0.55 (+1.03)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 116.19B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 109.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.25 (-0.44%)

USD 98.97B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.04 (-0.27%)

USD 63.27B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.45 (-0.19%)

USD 52.42B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.41 (+0.38%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.06 (-0.85%)

USD 38.52B
0ZC:F Zscaler Inc

+7.40 (+4.31%)

USD 37.92B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.15% 52% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.15% 49% F 50% F
Trailing 12 Months  
Capital Gain 8.58% 53% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.58% 49% F 50% F
Trailing 5 Years  
Capital Gain 45.45% 75% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.45% 74% C 54% F
Average Annual (5 Year Horizon)  
Capital Gain 11.00% 72% C 68% D+
Dividend Return 11.00% 70% C- 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.71% 64% D 89% A-
Risk Adjusted Return 102.69% 94% A 95% A
Market Capitalization 0.85B 73% C 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike